New smart chemo targets tumors, spares healthy tissue

NCT ID NCT07454642

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while reducing harm to healthy cells. The main goals are to check safety and find the right dose, with initial signs of effectiveness also being measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AVA6103, a targeted chemotherapy that activates inside tumors
What this could lead to
If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be effective or could have serious side effects. It is only tested in a small number of people with specific tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NEXT Oncology

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.